NCT06232590 is a NA clinical trial of Control Lens (comfilcon A) in Presbyopia, sponsored by CooperVision International Limited (CVIL).

Who is sponsoring NCT06232590?

NCT06232590 is sponsored by CooperVision International Limited (CVIL).

What drugs are being tested in NCT06232590?

Interventions in NCT06232590: Control Lens (comfilcon A), Test Lens (lehfilcon A).

What condition does NCT06232590 study?

NCT06232590 studies Presbyopia.

Is NCT06232590 still recruiting?

NCT06232590 is currently completed. Last updated 12 February 2025.

Are results published for NCT06232590?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-12 · How we verify

NCT06232590

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance Comparison of Two Monthly Replacement Silicone Hydrogel Multifocal Lens Types

Completed NA Results posted Last updated 12 February 2025

What this trial tests

NA trial testing Control Lens (comfilcon A) in Presbyopia in 60 participants. Completed in 9 July 2024.

Timeline

23 February 2024

Primary endpoint
9 July 2024

9 July 2024

Quick facts

Lead sponsor	CooperVision International Limited (CVIL)
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	23 February 2024
Primary completion	9 July 2024
Estimated completion	9 July 2024
Sites	5 locations across Canada, United States

Drugs / interventions tested

Control Lens (comfilcon A)
Test Lens (lehfilcon A)

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

CooperVision International Limited (CVIL) — full company profile →

Who can join

42 and older, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Lens Handling for Insertion Primary · 1 month

Subjective rating collected in office using a 0-100 scale, where 0=Very difficult and 100=Very easy. The participant rated the study lens considering a typical day in the last 1 month of wear.

Group	Value	95% CI
Control Lens	95	± 9
Test Lens	96	± 8

Adverse events — posted to ClinicalTrials.gov

Time frame: Length of study, approximately 3 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Control Lens

Serious: 0/60 (0%)

Deaths: 0/60

Test Lens

Serious: 0/59 (0%)

Deaths: 0/59

Other adverse events (7 terms — click to expand)

Reaction	System	Control Lens	Test Lens
Small lymph cysts	Eye disorders	—	—
Subconjunctival hemorrhage	Eye disorders	—	—
Eye floaters	Eye disorders	—	—
Respiratory infection	Respiratory, thoracic and mediastinal disorders	—	—
Stomach distress	Gastrointestinal disorders	—	—
Depression	Psychiatric disorders	—	—
Primary care provider intervention	Surgical and medical procedures	—	—

Data from ClinicalTrials.gov NCT06232590 adverse events section.

Sponsor's own description

To evaluate and compare the performance of two monthly replacement multifocal contact lenses in existing wearers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other CooperVision International Limited (CVIL) trials

Trials by the same sponsor.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07276347 — Comprehensive Assessment of Multiple Products (CAMP) · NA · completed
NCT07104773 — Clinical Investigation of Proclear® 1 Day and MyDay® Sphere Contact Lenses · NA · completed
NCT06873048 — Short-term Study of Two Soft Contact Lenses in Wearers With Low Astigmatism · NA · completed
NCT06869044 — A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06232590 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CooperVision International Limited (CVIL)
Last refreshed: 12 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232590.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing